BOLT BIOTHERAPEUTICS INC (BOLT)

US0977021049 - Common Stock

0.76  -0.01 (-1.2%)

After market: 0.75 -0.01 (-1.32%)

Fundamental Rating

3

Overall BOLT gets a fundamental rating of 3 out of 10. We evaluated BOLT against 582 industry peers in the Biotechnology industry. BOLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BOLT is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year BOLT has reported negative net income.
BOLT had a negative operating cash flow in the past year.
In the past 5 years BOLT always reported negative net income.
In the past 5 years BOLT always reported negative operating cash flow.

1.2 Ratios

BOLT has a Return On Assets of -44.11%. This is comparable to the rest of the industry: BOLT outperforms 54.42% of its industry peers.
BOLT has a Return On Equity (-60.52%) which is in line with its industry peers.
Industry RankSector Rank
ROA -44.11%
ROE -60.52%
ROIC N/A
ROA(3y)-38.01%
ROA(5y)-61.52%
ROE(3y)-50.72%
ROE(5y)-4098.34%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BOLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
BOLT has more shares outstanding than it did 1 year ago.
BOLT has more shares outstanding than it did 5 years ago.
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

BOLT has an Altman-Z score of -4.22. This is a bad value and indicates that BOLT is not financially healthy and even has some risk of bankruptcy.
BOLT's Altman-Z score of -4.22 is on the low side compared to the rest of the industry. BOLT is outperformed by 61.70% of its industry peers.
There is no outstanding debt for BOLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.22
ROIC/WACCN/A
WACC8.88%

2.3 Liquidity

BOLT has a Current Ratio of 5.68. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
BOLT has a Current ratio (5.68) which is comparable to the rest of the industry.
A Quick Ratio of 5.68 indicates that BOLT has no problem at all paying its short term obligations.
BOLT has a Quick ratio of 5.68. This is comparable to the rest of the industry: BOLT outperforms 58.58% of its industry peers.
Industry RankSector Rank
Current Ratio 5.68
Quick Ratio 5.68

6

3. Growth

3.1 Past

BOLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.50%, which is quite impressive.
The Revenue has grown by 68.00% in the past year. This is a very strong growth!
The Revenue has been growing by 224.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)23.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
Revenue 1Y (TTM)68%
Revenue growth 3Y224.73%
Revenue growth 5YN/A
Sales Q2Q%188.83%

3.2 Future

Based on estimates for the next years, BOLT will show a small growth in Earnings Per Share. The EPS will grow by 7.02% on average per year.
The Revenue is expected to grow by 47.59% on average over the next years. This is a very strong growth
EPS Next Y25.45%
EPS Next 2Y18.47%
EPS Next 3Y12.44%
EPS Next 5Y7.02%
Revenue Next Year17.67%
Revenue Next 2Y-26.77%
Revenue Next 3Y-5.92%
Revenue Next 5Y47.59%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

BOLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BOLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BOLT's earnings are expected to grow with 12.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.47%
EPS Next 3Y12.44%

0

5. Dividend

5.1 Amount

BOLT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (6/14/2024, 7:00:01 PM)

After market: 0.75 -0.01 (-1.32%)

0.76

-0.01 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap28.98M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.11%
ROE -60.52%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.68
Quick Ratio 5.68
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)23.5%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y25.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)68%
Revenue growth 3Y224.73%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y